Participant flow

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan · Source last updated 2024-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.

   id

   FG000

   title

   Pharmacists in Hospitals Prescribing NINLARO

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         330

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         330

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 24,000 pharmacists were requested to cooperate. Of these, 1329 pharmacists consented to participate in this study and 336 pharmacists passed the screening questions, out of which 6 pharmacists did not complete the questionnaire. 330 pharmacists were enrolled and completed all questions and were included in the analysis.

recruitment Details

Recruitment and response collection started on 01 June 2023 and ended on 09 June 2023.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice